Tyvyt (sintilimab)

P2, N=40, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting --> Recruiting

P2, N=120, Not yet recruiting, Sichuan University

Distinct clinical and metabolomic alterations are associated with sintilimab-induced rash in lung cancer patients. The identified differential metabolites may serve as predictive biomarkers and potential therapeutic targets, providing new insights for clinical management and mechanistic research into immune-related adverse events.

P2, N=32, Not yet recruiting, Peking University People's Hospital

P2, N=27, Not yet recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | N=40 --> 27 | Trial completion date: Sep 2027 --> Jun 2036 | Trial primary completion date: Apr 2027 --> Jun 2036

P2, N=107, Active, not recruiting, Tianjin Medical University Cancer Institute and Hospital

Specifically, the patient underwent six cycles of induction therapy with the etoposide plus cisplatin regimen combined with sintilimab, followed by intensity-modulated radiation therapy (pGTV 48 Gy, pCTV 48 Gy), and subsequently received maintenance sintilimab monotherapy. For this highly aggressive SMARCA4-deficient tumor, the sequential treatment strategy of "induction chemotherapy-immunotherapy followed by consolidative radiotherapy" enables long-term disease control, and immunotherapy maintenance also demonstrated significant value in delaying disease progression. The experience from this case could inform the diagnostic and therapeutic approach for this rare subtype of lung cancer.

P2, N=30, Recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting --> Recruiting

P1, N=16, Recruiting, Sun Yat-sen University

P2, N=23, Not yet recruiting, Sun Yat-sen University

P=N/A, N=1000, Active, not recruiting, Harbin Medical University

Following eight cycles of ifosfamide plus epirubicin chemotherapy, tumor burden was reduced by more than 90%. Although first-line chemotherapy produced marked pulmonary tumor regression, subsequent anlotinib maintenance therapy did not prevent disease progression. In this PD-L1-positive tumor (CPS 10), sintilimab-based combination therapy yielded a marked clinical and radiographic response, supporting further investigation of ICI-based therapy in selected patients with metastatic MPT.